Benign Prostatic Hyperplasia Treatment Global Market Report 2025

The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to increasing awareness and screening initiatives, the rising prevalence of BPH, greater healthcare awareness, improvements in healthcare infrastructure, and the growing elderly population.

The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $10.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the rising adoption of minimally invasive procedures, an increasing number of geriatric patients, greater availability of advanced treatment options, a growing focus on patient-centric care, and a rising prevalence of comorbidities. Key trends expected during this period include the development of targeted therapies, integration of digital health solutions, innovations in surgical options, the use of 3D imaging for diagnosis, and advancements in patient-centered care models.

The increasing adoption of minimally invasive surgeries is expected to drive the growth of the benign prostatic hyperplasia (BPH) treatment market. These procedures involve small or no incisions, using specialized instruments to minimize recovery time, pain, and the risk of complications. The growing preference for minimally invasive surgeries is attributed to benefits such as shorter recovery times, reduced pain, lower risk of complications, and improved cosmetic outcomes. BPH treatment through minimally invasive procedures offers patients effective symptom relief with fewer complications and faster recovery. For example, in September 2023, the American Society of Plastic Surgeons (ASPS), a US-based professional association, reported that 23,672,269 cosmetic minimally invasive procedures were performed globally in 2022, including treatments such as neuromodulator injections, lip augmentation, and non-invasive skin tightening. Consequently, the increasing adoption of minimally invasive surgeries is fueling the growth of the BPH treatment market.

Leading companies in the BPH treatment market are focusing on innovative solutions, particularly minimally invasive procedures, to improve patient outcomes and reduce recovery times. These techniques involve minimal or no incisions, reducing trauma, pain, and complications while ensuring faster recovery compared to traditional surgical methods. For instance, in December 2022, Teleflex Incorporated, a US-based medical device company, introduced the UroLift System for BPH treatment. This system uses small permanent implants to reposition enlarged prostate tissue, providing significant symptom relief without requiring tissue removal, cutting, or heating. As an outpatient treatment, it allows for rapid recovery, preserves sexual function, and delivers superior symptom relief compared to conventional BPH medications, with side effects typically resolving within two to four weeks.

In October 2023, Laborie Medical Technologies, Inc., a US-based medical technology company, acquired Urotronic for $600 million. This acquisition aims to expand Laborie’s interventional urology portfolio, enhance its technological capabilities, and strengthen its global presence in minimally invasive urological treatments. Urotronic, Inc., a US-based medical device company, specializes in developing and marketing minimally invasive treatments for BPH.

Major players in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, and Butterfly Medical Ltd.

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in benign prostatic hyperplasia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the benign prostatic hyperplasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Benign prostatic hyperplasia (BPH) treatment encompasses medical, minimally invasive, and surgical approaches aimed at managing symptoms of an enlarged prostate. BPH is a common condition among aging men, often causing urinary problems such as frequent urination, weak stream, and incomplete bladder emptying.

The primary treatment options for BPH include minimally invasive surgery (MIS) and invasive surgery. Minimally invasive surgery (MIS) utilizes small incisions, specialized instruments, and advanced imaging technology to perform procedures with minimal trauma. The therapeutic classes for BPH treatment consist of alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other therapeutic categories. These treatments serve various end users, including home healthcare, hospitals and clinics, as well as research and manufacturing facilities.

The benign prostatic hyperplasia treatment market research report is one of a series of new reports that provides benign prostatic hyperplasia treatment market statistics, including the benign prostatic hyperplasia treatment industry's global market size, regional shares, competitors with a benign prostatic hyperplasia treatment market share, detailed benign prostatic hyperplasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The benign prostatic hyperplasia treatment market consists of revenues earned by entities by providing services such as pharmacological treatments, minimally invasive procedures, surgical treatments, diagnostic services, and prostatic stents. The market value includes the value of related goods sold by the service provider or included within the service offering. The benign prostatic hyperplasia treatment market also includes sales of transurethral microwave thermotherapy, prostatic urethral lift, acupuncture, combination therapy, phosphodiesterase-5 inhibitors, and minimally invasive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.